A detection method of breast milk oligosaccharide

HK40137320APending Publication Date: 2026-09-11FEIHE (AR HORQIN BANNER) DAIRY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK42026126491
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-07-22
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202610458586.9 (22) Application Date 2026.04.09 (71) Applicant Feihe (Arukorqin Banner) Dairy Co., Ltd. Address 025550 Fifth Commercial Hall, East Side of South Gate, Fengjing A District, Arukorqin Banner, Chifeng City, Inner Mongolia Autonomous Region Applicant Heilongjiang Feihe Dairy Co., Ltd. (72) Inventors Zhang Xuguang, Wang Xiangxin, Wei Qiaosi, Du Yutong, Ma Xinming, Xie Qinggang, Jiang Shilong, Lu Siyu (74) Patent Agency Beijing Grobar Intellectual Property Agency (General Partnership) 11406 Patent Attorney Xiang Junhua (51) Int.Cl. G01N 27 / 447 (2006.01) G01N 21 / 64 (2006.01) (54) Invention Title: A Method for Detecting Human Milk Oligosaccharides (57) Abstract: This invention discloses a method for detecting human milk oligosaccharides. The method includes a step of detecting a sample using a capillary electrophoresis-laser-induced fluorescence detection method. The running buffer used in the capillary electrophoresis-laser-induced fluorescence detection method contains Tris-base, EDTA, urea, and greater than 2% (m / V) and less than 4% (m / V) of PVP and greater than 5% (m / V) and less than 15% (m / V) of boric acid. The detection method provided by this invention can be applied to the separation and detection of acidic and neutral HMOs isomers in samples to be tested (e.g., breast milk and infant formula samples). Claims 1 page, Description 17 pages, Drawings 7 pages, CN 121994899 A 2026.05.08 CN 1 21 99 48 99 A 1. A method for detecting human milk oligosaccharides, characterized in that the method includes a step of detecting the sample using a capillary electrophoresis-laser induced fluorescence detection method, wherein the running buffer used in the capillary electrophoresis-laser induced fluorescence detection method comprises Tris-base, EDTA, urea, and greater than 2% (m / V) and less than 4% (m / V) of PVP and greater than 5% (m / V) and less than 15% (m / V) of boric acid. 2. The method for detecting human milk oligosaccharides according to claim 1, characterized in that the running buffer comprises 70-100 mmol / L Tris-base, 1-5 mmol / L EDTA and / or 2-10 mol / L urea. 3. The method for detecting human milk oligosaccharides according to claim 1 or 2, characterized in that, before the step of detecting the sample using a detection method based on capillary electrophoresis-laser induced fluorescence, it further includes preparing the sample...The method for detecting human milk oligosaccharides according to claim 3 is characterized in that, in the sample purification step, the sample to be tested is purified by alcohol precipitation and solid phase extraction column; and / or, in the sample derivatization step, the sample to be tested is derivatized by reductive amination derivatization method. 5. The method for detecting human milk oligosaccharides according to claim 1 or 2 is characterized in that, in the step of detecting the sample to be tested using a detection method based on capillary electrophoresis-laser induced fluorescence, the capillary electrophoresis is performed at a voltage not lower than 15 kV. 6. The method for detecting human milk oligosaccharides according to claim 1 or 2 is characterized in that, in the step of detecting the sample to be tested using a detection method based on capillary electrophoresis-laser induced fluorescence, the capillary is operated at a temperature greater than 25 °C during capillary electrophoresis, and / or, the sample pan is maintained at a temperature of 10-25 °C. 7. The method for detecting human milk oligosaccharides according to claim 1 or 2, wherein the capillary is a chemically inert and hydrophobic capillary. 8. The method for detecting human milk oligosaccharides according to claim 1 or 2, wherein the sample to be tested includes milk and / or dairy products. 9. The method for detecting human milk oligosaccharides according to claim 1 or 2, wherein the human milk oligosaccharides include neutral human milk oligosaccharides and acidic human milk oligosaccharides composed of sialic acid. 10. The method for detecting human milk oligosaccharides according to claim 9, wherein the human milk oligosaccharides include at least one of lactose-N-fucopentose I, lactose-N-tetrasaccharide, 2'-fucosylated lactose, lactose-N-neotetrasaccharide, 3,2'-difucosylated lactose, disialyllactose-N-tetrasaccharide, 3-fucosylated lactose, 3'-sialic acid lactose, and 6'-sialic acid lactose. Claims 1 / 1 page 2 CN 121994899 A A Method for Detecting Human Milk Oligosaccharides Technical Field

[0001] This invention belongs to the field of human milk oligosaccharide detection, specifically relating to a method for detecting human milk oligosaccharides, and more specifically to a CE-LIF method for simultaneously separating and detecting the content of 9 kinds of human milk oligosaccharides in dairy products. Background Art

[0002] Human milk oligosaccharides (HMOs) are important bioactive compounds in breast milk, and are the third largest solid component after lactose and lipids, with a concentration usually of 5-20 g / L. These complex carbohydrates play a variety of roles in infant health, including promoting beneficial intestinal flora and regulating immune responses. Due to their unique functional properties, HMOs are increasingly being added to infant formula and dietary supplements to mimic the protective effects of breast milk. Currently, more than 200 kinds of human milk oligosaccharides have been identified.Oligosaccharides (HMOs), of which over 140 structures have been elucidated, are structurally based on five main monosaccharide building blocks. Their core backbone is lactose (Lac) at the reducing end, which can be further derivatized by introducing fuc or sialic acid (Neu5Ac) residues through different glycosidic bond linkages, resulting in isomers with the same molecular weight but different structures. These isomers mainly include positional isomers, such as 2'-fucosylated lactose (2'-FL) and 3-fucosylated lactose (3-FL), and 3'-sialylated lactose (3'-SL) and 6'-sialylated lactose (6'-SL); they also include linkage isomers, such as lactose-N-tetrasaccharide (LNT) and lactose-N-neotetrasaccharide (LNnT). This high structural complexity and diversity of isomers present significant technical challenges to the analysis and detection of HMOs.

[0003] Currently, researchers have employed various analytical techniques to characterize HMOs, but their complex structures, lack of UV-absorbing groups, and the fact that some components are electrically neutral present unique challenges for analysis and detection. In recent years, liquid chromatography-mass spectrometry (LC-MS) has been increasingly widely used in HMO analysis, especially the LC-MS method using porous graphitized carbon as the stationary phase, which can achieve simultaneous quantitative analysis of neutral and acidic HMOs, significantly improving analytical throughput and structural resolution. However, this method still faces challenges in distinguishing structurally very similar linked isomers. In addition, traditional chromatographic methods generally use large amounts of organic mobile phase, and the resulting waste liquid not only increases operating costs but also reduces the environmental friendliness of the method. Overall, although existing analytical methods have made significant progress in HMO detection, how to achieve efficient separation of key isomers in complex matrices while simultaneously considering analytical throughput, sensitivity, and green chemistry requirements remains a problem that urgently needs to be solved in current research.

[0004] Given the wide concentration range of HMOs in breast milk, the detection method must possess both a wide linear dynamic range and high sensitivity. Capillary electrophoresis (CE) has become an effective supplementary platform to chromatographic methods due to its high separation efficiency, short analysis time, low sample consumption, and simple pretreatment. To address the problem of HMOs lacking chromophores or fluorophores for optical detection, the introduction of laser-induced fluorescence (LIF) detection technology provides a solution. By using fluorescent labels (such as trisodium 8-aminopyrene-1,3,6-trisulfonate, APTS) to derivatize HMOs, not only are the necessary charges provided for their migration in an electric field, but the detection sensitivity of CE is also significantly improved.

[0005] Specific buffer solutions are crucial for the separation effect of CE. Reference 1 discloses that while conventional CE matrices (such as HR-NCHO) can separate LNT and LNnT, they cannot effectively distinguish between 2'-FL and 3-FL. Adding a background electrolyte of borate through boron...The complexation of acid salts and diols provides higher separation. Due to the difference in the three-dimensional structure of 2'-FL and 3-FL, their complexing ability with borate is different, resulting in a difference in apparent mobility, thus achieving effective separation of the two. In addition, CE technology itself has the characteristics of miniaturization and low waste volume, which is more in line with the requirements of green analytical chemistry.

[0006] Although there have been studies that have used CE for the detection of HMOs, there are still limitations. Specification 1 / 17 pages 3 CN 121994899 A

[0007] Poor separation effect: Reference 2 developed a laser-induced fluorescence detection capillary electrophoresis (CE-LIF) method, but it was only used to analyze neutral sugars in breast milk. In this study, 300 mM borate buffer was used as background electrolyte to separate five selected oligosaccharides and other sugars. At the same time, the validation of this method was limited to the estimation of linearity and sensitivity. Reference 3 describes a capillary electrophoresis method with laser-induced fluorescence detection; however, this method only detects three oligosaccharides (DSLNT, 3'-SL, and 6'-SL) in colostrum samples.

[0008] Existing instrument detection methods all exhibit complex reaction systems: at the separation level, there is currently no single CE condition that can simultaneously separate all key HMO isomers. Therefore, it is necessary to perform two analyses on the same sample, using both conventional and borate-type CE matrices, to achieve comprehensive separation of HMO isomers. To date, there is no CE separation method with fluorescence detection that can be used to simultaneously separate and detect the main neutral HMOs and acidic HMOs composed of sialic acid. Cited documents

[0010] Cited documents 1: Sarkozy D, Borza B, Domokos A, Varadi E, Szigeti M, Meszaros-Matwijuk A, Molnar-Gabor D, Guttman A. Ultrafast High-Resolution Analysis of Human Milk Oligosaccharides by Multicapillary Gel Electrophoresis [J]. Food Chemistry, 2021, 341:128200. Reference document 2: Song J-F, Weng M-Q, Wu S-M, Xia Q-C. Analysis of neutral saccharides in human milk derivatized with 2-aminoacridone by capillary electrophoresis withlaser‑induced fluorescence detection[J]. Analytical biochemistry, 2002, 304(1): 126‑129. Cited document 3: Rusin M, , Dobrowolska-Iwanek J, Huras H, , et al. Development of a capillary electrophoresis method with laser-induced fluorescence detection for the characterization of oligosaccharides in human milk[J]. Monatshefte für Chemie-Chemical Monthly, 2024, 155(8): 825‑834. Summary of the Invention

[0013] Problems to be Solved by the Invention

[0014] As mentioned above, the existing CE-LIF technology has a key bottleneck: conventional CE matrices (such as commercially available HR-NCHO matrices) can separate LNT / LNnT, but cannot separate 2'-FL / 3-FL; although borate matrices can solve the problem of 2'-FL / 3-FL separation, they will cause LNT / LNnT co-migration, requiring two analyses of the same sample to cover the key isomers.

[0015] It can be seen that the existing technology is difficult to efficiently achieve the simultaneous separation and accurate detection of nine HMOs in breast milk and infant formula, namely 6'-sialyl lactose (6'-SL), disialial lactose-N-tetrasaccharide (DSLNT), 3'-sialyl lactose (3'-SL), 3-fucosylated lactose (3-FL), 3,2'-difucosylated lactose (DFL), lactose-N-neotetrasaccharide (LNnT), 2'-fucosylated lactose (2'-FL), lactose-N-tetrasaccharide (LNT), and lactose-N-fucopentose I (LNFP I). There is an urgent need to develop new detection methods to overcome the above limitations.

[0016] Solution to the problem

[0017] [1]. A method for detecting human milk oligosaccharides, wherein the method for detecting human milk oligosaccharides includes a step of detecting a sample to be tested using a capillary electrophoresis-laser induced fluorescence detection method, wherein the running buffer used in the capillary electrophoresis-laser induced fluorescence detection method contains Tris-base, EDTA, urea, and PVP greater than 2% (m / V) and less than 4% (m / V) and boric acid greater than 5% (m / V).

[0018] [2].According to the method for detecting human milk oligosaccharides according to [1], the running buffer contains less than 15% (m / V) boric acid.

[0019] [3]. According to the method for detecting human milk oligosaccharides according to [1] or [2], the running buffer contains 70-100 mmol / L Tris-base, 1-5 mmol / L EDTA and / or 2-10 mol / L urea.

[0020] [4]. According to any one of [1]-[3], the method for detecting human milk oligosaccharides further includes a pretreatment step of the sample before the step of detecting the sample using a capillary electrophoresis-laser induced fluorescence detection method; optionally, the pretreatment step includes a sample purification step and / or a sample derivatization step.

[0021] [5]. The method for detecting human milk oligosaccharides according to [4], wherein, in the sample purification step, the sample to be tested is purified by alcohol precipitation and solid phase extraction column; and / or, in the sample derivatization step, the sample to be tested is derivatized by reductive amination derivatization method.

[0022] [6]. The method for detecting human milk oligosaccharides according to any one of [1]-[5], wherein, in the step of detecting the sample to be tested using a detection method based on capillary electrophoresis-laser induced fluorescence, the capillary electrophoresis is performed at a voltage of not less than 15 kV, preferably at a voltage of not less than 20 kV.

[0023] [7]. The method for detecting human milk oligosaccharides according to any one of [1]-[6], wherein, in the step of detecting the sample to be tested using a detection method based on capillary electrophoresis-laser induced fluorescence, the capillary in the capillary electrophoresis is operated at a temperature greater than 25 °C, preferably at a temperature less than 35 °C, and / or, the sample pan is maintained at a temperature of 10-25 °C.

[0024] [8]. The method for detecting human milk oligosaccharides according to any one of [1]-[7], wherein the capillary is a chemically inert and hydrophobic capillary; preferably, the capillary is a capillary with a fluorocarbon polymer coating.

[0025] [9]. The method for detecting human milk oligosaccharides according to any one of [1]-[8], wherein the sample to be tested includes milk and / or dairy products.

[0026]

[10] . A method for detecting human milk oligosaccharides according to any one of [1]-[9], wherein the human milk oligosaccharides include neutral human milk oligosaccharides and acidic human milk oligosaccharides composed of sialic acid; optionally, the human milk oligosaccharides include lactose-N-fucopentose I (LNFP I), lactose-N-tetrasaccharide (LNT), 2'-fucosylated lactose (2'-FL), and lactose-N-neotetrasaccharide.(LNnT), 3,2'-difucosyllactose (DFL), disialyllactose-N-tetrasaccharide (DSLNT), 3-fucosyllactose (3-FL), 3'-sialyllactose (3'-SL), and 6'-sialyllactose (6'-SL).

[0027] Effects of the Invention

[0028] The detection method provided by the present invention can be applied to the separation and detection of acidic and neutral HMOs isomers in samples to be tested (e.g., breast milk and infant formula samples).

[0029] Compared with the prior art, the detection method of the present invention has the following advantages.

[0030] In some embodiments, the present invention provides a capillary electrophoresis detection method and its running buffer for the separation and quantification of nine human milk oligosaccharides in breast milk and infant formula, solving the problems of low separation efficiency, severe peak overlap, and double analysis of the same sample in the existing methods. The detection method uses a running buffer with added PVP reagent to cause polymer chains to intertwine and form transient sieves, which can sieve oligosaccharide molecules and effectively improve the separation degree of human milk oligosaccharides.

[0031] In some embodiments, the running buffer used in the detection method of the present invention affects the interaction between the analyte and the buffer by adjusting the amount of boric acid added, reducing sample diffusion, especially in scenarios with narrow separation bandwidth, which can significantly improve peak sharpness and separation degree; on the other hand, the unique chemical properties of boric acid enable it to form complexes with analytes with cis-diol structures (such as sugars, some polysaccharide-modified biomacromolecules), changing the effective charge / size ratio of such analytes, thereby adjusting their electrophoretic migration rate and achieving selective separation of components that are difficult to separate by traditional methods.

[0032] In some embodiments, the running buffer used in the detection method of the present invention achieves the separation and quantification of at least 9 human milk oligosaccharides by combining specific amounts of PVP and boric acid.

[0033] In some preferred embodiments, the selection of μSIL-FC coated capillary, the adjustment of key electrophoresis parameters, and / or the combination of fluorescence detection and sample derivatization in the detection method of the present invention can achieve efficient separation of at least nine kinds of human milk oligosaccharides in breast milk and infant formula. Compared with traditional HR-NCHO matrix and borate-containing matrix methods, the present invention shows significant advantages in separating human milk oligosaccharides with similar structures (such as LNT / LNnT, 2'-FL / 3-FL), and is suitable for scenarios such as breast milk nutrient analysis, infant formula quality control and label compliance verification, and component detection of oligosaccharide functional foods, and has good versatility, stability and promotional value.

[0034] In some preferred embodiments, the precipitation of supercooled ethanol and the purification effect of the amino column involved in the detection method of the present invention can effectively remove proteins, lactose and other substances that may be present in the sample to be tested (e.g., breast milk or infant formula).Interfering substances. Eluting with an acetonitrile-water solution containing a specific ratio maximizes lactose removal, retains HMOs, and avoids masking of low-abundance HMO peaks by interference. Figure Descriptions

[0035] Figure 1: Electrophoresis spectra of mixed standards under different PVP concentrations (2%, 3%, 4%) in separation buffer.

[0036] Figure 2: Electrophoresis spectra of mixed standards under different boric acid concentrations (1%, 5%, 10%) in separation buffer.

[0037] Figure 3: Electrophoresis spectra of mixed standards under different separation voltages (15, 20, 30 kV).

[0038] Figure 4: Electrophoresis spectra of mixed standards under different separation temperatures (20, 25, 30, 35 ℃).

[0039] Figure 5: Linear range of 9 human milk oligosaccharide mixed standards.

[0040] Figure 6: Electrophoresis spectra of breast milk samples.

[0041] Figure 7: Electrophoresis spectra of infant formula samples. Detailed Description of Embodiments

[0042] Various exemplary embodiments, features, and aspects of the present invention will now be described in detail. The term “exemplary” as used herein means “serving as an example, embodiment, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as superior to or better than other embodiments.

[0043] Furthermore, numerous specific details are set forth in the following detailed description of the invention to better illustrate the invention. Those skilled in the art will understand that the invention can be practiced without certain specific details. In other instances, methods, means, apparatus, and steps well known to those skilled in the art have not been described in detail in order to highlight the spirit of the invention.

[0044] Unless otherwise stated, all units used in this specification are International Standard Units (SI), and all numerical values ​​and ranges appearing in this invention should be understood to include systematic errors unavoidable in industrial production.

[0045] In this specification, the word “may” has both the meaning of performing a certain process and not performing a certain process.

[0046] In this specification, the terms "some specific / preferred embodiments," "other specific / preferred embodiments," "implementation," etc., refer to specific elements (e.g., features, structures, properties, and / or characteristics) related to the described embodiment, which are included in at least one embodiment described herein and may exist in other embodiments or may not exist in other embodiments. Furthermore, it should be understood that the elements may be combined in any suitable manner in various embodiments.

[0047] In this specification, the numerical range expressed as "numerical value A to numerical value B" refers to a range including the endpoints A and B.

[0048] Method for detecting human milk oligosaccharides

[0049] In some aspects of this specification, a method for detecting human milk oligosaccharides is provided, wherein the human milk oligosaccharides...The detection method includes the step of detecting the sample using a capillary electrophoresis-laser induced fluorescence detection method, wherein the running buffer used in the capillary electrophoresis-laser induced fluorescence detection method contains Tris-base, EDTA, urea, and 2.5-3.5% (m / V) PVP and greater than 5% (m / V) boric acid.

[0050] The detection method for human milk oligosaccharides provided by the present invention can separate and quantify at least 9 kinds of human milk oligosaccharides, solving the problems of low separation efficiency, severe peak overlap, and double analysis of the same sample in existing methods.

[0051] Sample source

[0052] In the detection method provided by the present invention, there are no special restrictions on the test sample. For example, it can be milk, dairy products, or any other sample containing human milk oligosaccharides, such as food samples.

[0053] In the present invention, "milk" refers to the liquid produced by the mammary glands of mammals, such as human (breast milk), cow (e.g., dairy cow), goat, sheep, or camel.

[0054] In the present invention, "dairy products" refers to any food in which one of the main components is based on milk.

[0055] In this invention, there is no particular limitation on the source of "dairy products," which can refer to food products produced by animals such as cows, goats, sheep, yaks, horses, camels, and other mammals.

[0056] Examples of dairy products are low-fat milk (e.g., 0.1%, 0.5%, or 1.5% fat), nonfat milk, milk powder, whole milk, whole milk products, butter, buttermilk, buttermilk products, skim milk, skim milk products, high-fat products, condensed raw milk, fresh cream, cheese, ice cream and dessert products, probiotic beverages, or probiotic yogurt-type beverages. "Milk powder" refers to artificial dairy products made by evaporating milk to dryness. In some preferred embodiments of this invention, the samples in the detection method of this invention are derived from cow or sheep milk powder products, as well as breast milk.

[0057] Pretreatment

[0058] In the detection method of this invention, before detecting the sample to be tested using the capillary electrophoresis-laser induced fluorescence detection method, a pretreatment step for the sample to be tested is included.

[0059] In some embodiments, the pretreatment step includes a sample purification step and a sample derivatization step.

[0060] Sample Purification Step

[0061] In some embodiments, the sample purification step of the detection method provided by the present invention reduces the presence of proteins, lactose, salts, and other possible interferences in the sample by means of alcohol precipitation and solid-phase extraction column (e.g., normal-phase silica-bonded amino solid-phase extraction column, hereinafter referred to as: amino column).

[0062] In some specific embodiments, in the sample purification step, the sample to be tested is weighed, and supercooled ethanol is added to remove protein impurities. The supernatant is centrifuged and acetonitrile solution is added to construct an organic phase dissolution system. The test solution is purified using an amino column, and an appropriate amount of eluent is taken, dried by nitrogen blowing, and the dried sample is awaited for subsequent derivatization.

[0063] In some embodiments, the ratio of the test sample to supercooled ethanol is 50-300 mg : 100-600 μL. In some preferred embodiments, the mass-to-volume ratio of the test sample to supercooled ethanol is 1:2.

[0064] In other embodiments, the ratio of the test sample to supercooled ethanol is 0.5-3 mL : 1-6 mL. In some preferred embodiments, the volume ratio of the test sample to supercooled ethanol is 1:2.

[0065] In some exemplary embodiments, for milk powder samples, milk powder and water can be mixed to form a substantially homogeneous system, followed by subsequent necessary processing. For example, 200-800 mg of milk powder is mixed with 1-5 mL of water.

[0066] In some embodiments, for breast milk samples, 100±10 mg of breast milk sample is weighed into a centrifuge tube, and 200±20 μL of supercooled ethanol is added, preferably maintaining a mass-to-volume ratio of sample solution to supercooled ethanol of 1:2, and mixed thoroughly. The mixture is centrifuged at 8000±1000 rpm / min for 5±2 min. 210±10 μL of the supernatant is taken into a centrifuge tube, and 1.89±0.09 mL of acetonitrile is added, preferably maintaining a volume ratio of supernatant to acetonitrile of 1:9, and mixed thoroughly. The mixture is then collected and awaits purification.

[0067] In some exemplary embodiments, for breast milk samples, 100 mg of breast milk sample is weighed into a 1.5 mL centrifuge tube, and 200 μL of supercooled ethanol is added, and mixed thoroughly. The mixture is centrifuged at 8000 rpm / min for 5 min. 210 μL of the supernatant is taken into a 15 mL centrifuge tube, and 1.89 mL of acetonitrile is added, and the mixture is collected and awaits purification.

[0068] In some embodiments, for the milk powder sample, 500±100 mg of milk powder is weighed into a centrifuge tube, 3±1 mL of water at 40±5 °C is added, and the mixture is vortexed until the milk powder is completely dissolved. Water is then added to bring the volume to 5 mL. 1±0.2 mL of the sample solution is taken and 2±0.4 mL of supercooled ethanol is added, preferably maintaining a volume ratio of 1:2 between the sample solution and supercooled ethanol, and the mixture is thoroughly mixed. The mixture is centrifuged at 8000±1000 rpm / min for 5±2 min. 1.2±0.2 mL of the supernatant is taken into a centrifuge tube, and 10.8±1.8 mL of acetonitrile is added, preferably maintaining a volume ratio of 1:9 between the supernatant and acetonitrile, and the mixture is thoroughly mixed and collected for purification.

[0069] In some exemplary embodiments, for a milk powder sample, 500 mg of milk powder is weighed into a 15 mL centrifuge tube, 3 mL of 40 °C water is added, and the mixture is vortexed until the milk powder is completely dissolved. Water is then added to bring the volume to 5 mL. 1 mL of the sample solution is taken and 2 mL of supercooled ethanol is added, and the mixture is thoroughly mixed. The mixture is then centrifuged at 8000 rpm / min for 5 minutes.min. Take 1.2 mL of the supernatant into a 15 mL centrifuge tube, add 10.8 mL of acetonitrile, mix well, collect and wait for purification.

[0070] In some embodiments, after the amino column is activated, the sample is loaded and the amino column is washed with an aqueous solution of acetonitrile containing ammonium formate to remove lactose.

[0071] In some preferred embodiments, the ammonium formate content in the aqueous solution of acetonitrile containing ammonium formate is 5~20 mM, preferably 10~20 mM, for example 10 mM, 15 mM, 20 mM.

[0072] In some preferred embodiments, the aqueous solution of acetonitrile containing ammonium formate is 80~90% (V / V) aqueous solution of acetonitrile, preferably 83~86% (V / V) aqueous solution of acetonitrile, for example 83% (V / V) aqueous solution of acetonitrile, for example 84% (V / V) aqueous solution of acetonitrile, for example 85% (V / V) aqueous solution of acetonitrile, for example 86% (V / V) aqueous solution of acetonitrile.

[0073] In some exemplary embodiments, the amino column is activated with 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution and 3 mL of 85% (V / V) acetonitrile aqueous solution, respectively. The sample to be tested is transferred and passed through the column, washed twice with 3 mL of 85% (V / V) acetonitrile aqueous solution containing 15 mM ammonium formate (pH 4.4), and eluted with 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution. The eluent is collected. The volume is adjusted to 3.0 mL with 1% (V / V) trifluoroacetic acid aqueous solution and vortexed. 200 μL of the eluent is taken and dried under nitrogen at 50 °C. The dried sample is left for subsequent derivatization.

[0074] In some embodiments, in the detection scheme of the present invention, the precipitation of supercooled ethanol and the purification effect of the amino column can effectively remove proteins, lactose and other possible interfering substances from the sample to be tested (e.g., breast milk or infant formula). In some preferred embodiments, rinsing with an aqueous solution containing a specific proportion of acetonitrile maximizes the removal of lactose, retains HMOs, and avoids interference masking of low-abundance HMOs peaks.

[0075] Sample derivatization step

[0076] In some embodiments, in the sample derivatization step of the detection method provided by the present invention, the sample obtained in the sample purification step is derivatized using a reductive amination derivatization method.

[0077] In some specific embodiments, the derivatizing reagent APTS is added to the sample obtained in the sample purification step, acetic acid is added additionally, and then the reducing agent sodium cyanoborohydride is added, and the mixture is heated until the liquid evaporates to dryness.

[0078] In some specific embodiments, in the sample dried by rotary evaporation in the sample purification step, 18±3 μL of 48 Specification 6 / 17 Page 8 CN 121994899 A ±5 mM APTS (5±1 mg APTS dissolved in 200±50 μL 20±5% (V / V) acetic acid) is added, 5±2 μL of acetic acid is added additionally, and then 2±1 μL of1 mol / L sodium cyanoborohydride, vortexed to reconstitute, then heated at 60±5 °C with the lid off until the liquid evaporates to dryness.

[0079] In some specific embodiments, during the sample purification step, 18 μL of 48 mM APTS (5 mg APTS dissolved in 200 μL of 20% (V / V) acetic acid) is added to the vortexed sample, an additional 5 μL of acetic acid is added, and then 2 μL of sodium cyanoborohydride is added. After vortexing to reconstitute, the sample is heated at 60 °C with the lid off until the liquid evaporates to dryness.

[0080] In some embodiments, after the sample derivatization step is completed (after labeling), 100 μL of deionized water is added to reconstitute.

[0081] Capillary electrophoresis-laser induced fluorescence detection method

[0082] Running buffer

[0083] In this specification, the capillary electrophoresis-laser induced fluorescence detection method is also referred to as the laser-induced fluorescence detection capillary electrophoresis method, the capillary electrophoresis method with laser-induced fluorescence detection, or CE-LIF. The detection method for capillary electrophoresis-laser induced fluorescence is described, for example, in reference 1.

[0084] In some preferred embodiments, the running buffer (the matrix for capillary electrophoresis) contains 2.1-3.9% (m / V) PVP, preferably 2.2-3.8% (m / V) PVP, more preferably 2.3-3.7% (m / V) PVP, even more preferably 2.4-3.6% (m / V) PVP, and even more preferably 2.5-3.5% (m / V) PVP.

[0085] In some more preferred embodiments, the running buffer (the matrix for capillary electrophoresis) contains 2.8-3.3% (m / V) PVP, for example 2.8% (m / V) PVP, 2.9% (m / V) PVP, 3% (m / V) PVP, 3.1% (m / V) PVP, 3.2% (m / V) PVP, and 3.3% (m / V) PVP.

[0086] In some embodiments, the CAS No. of polyvinylpyrrolidone (PVP) is 9003-39-8; the molecular formula is (C6H9NO)n; and the structural formula is as follows: .

[0087] In some embodiments, the weight-average molecular weight Mw of PVP is 1,000,000-2,000,000, preferably 1,000,000-1,500,000, for example 1,100,000, 1,300,000, 1,500,000.

[0088] Adding PVP reagent, especially a specific amount of PVP, to the running buffer used in the detection method of the present invention causes the polymer chains to intertwine, forming transient sieves, which plays a role in sieving oligosaccharide molecules and effectively improves the separation degree of human milk oligosaccharides.

[0089] In some preferred embodiments, the running buffer contains less than 15% (m / V) boric acid.

[0090] In some preferred embodiments, the running buffer contains 5-15% (m / V) boric acid.

[0091] In some further preferred embodiments, the running buffer contains 8-12% (m / V) boric acid, for example, 8% (m / V) boric acid, 9% (m / V) boric acid, 10% (m / V) boric acid, 11% (m / V) boric acid, or 12% (m / V) boric acid.

[0092] In some embodiments, the CAS No. of boric acid is 10043-35-3; the molecular formula is H3BO3; and the structural formula is as follows: . Specification 7 / 17 page 9 CN 121994899 A

[0093] Adding a specific amount of boric acid to the running buffer used in the method of the present invention affects the interaction between the analyte and the buffer, reduces sample diffusion, and can significantly improve peak sharpness and resolution, especially in scenarios with narrow separation bandwidth. Furthermore, the unique chemical properties of boric acid allow it to form complexes with analytes having a cis-diol structure (such as sugars and partially polysaccharide-modified biomacromolecules), altering the effective charge / size ratio of these analytes and thus adjusting their electrophoretic migration rate, achieving selective separation of components that are difficult to separate using traditional methods. Further, specific amounts of boric acid and PVP result in even better separation.

[0094] In some embodiments, the running buffer contains 70-100 mmol / L Tris-base, preferably 75-95 mmol / L Tris-base, more preferably 80-95 mmol / L Tris-base, for example 80 mmol / L Tris-base, 85 mmol / L Tris-base, 89 mmol / L Tris-base.

[0095] In some embodiments, the CAS No. of Tris-base is 77-86-1; the molecular formula is NH2C(CH2OH)3; and the structural formula is as follows:

[0096] In some embodiments, the running buffer contains 1-5 mmol / L EDTA, preferably 1-4 mmol / L EDTA, more preferably 1-3 mmol / L EDTA, such as 1 mmol / L EDTA, 2 mmol / L EDTA, or 3 mmol / L EDTA.

[0097] In some embodiments, the CAS No. of EDTA is 60-00-4; the molecular formula is (HO2CCH2)2NCH2CH2N(CH2CO2H)2; and the structural formula is as follows:

[0098] In some embodiments, the running buffer contains 2-10 mol / L urea, preferably 2-8 mol / L urea, more preferably 2-6 mol / L urea, such as 2 mol / L urea, 4 mol / L urea, or 4 mol / L urea.Urea, 6 mol / L urea.

[0099] In some embodiments, the CAS No. of urea is 57-13-6; the molecular formula is NH2CONH2; the structural formula is as follows: .

[0100] Capillary electrophoresis

[0101] In some embodiments, the capillary electrophoresis is performed at a voltage of not less than 15 kV, preferably at a voltage of not less than 20 kV.

[0102] In some preferred embodiments, the capillary electrophoresis is performed at a voltage of 20-30 kV, preferably 25-30 kV, for example 25 kV, 28 kV, 30 kV.

[0103] In some exemplary embodiments, the sample to be tested is injected at 3±1 kV for 10±3 seconds. After injection, a voltage ramp is set for 2±1 minutes to rise to a voltage of 20-30 kV, preferably 30 kV.

[0104] In some embodiments, the capillary is operated at a temperature greater than 25°C during capillary electrophoresis.

[0105] In some embodiments, the capillary is operated at a temperature less than 35°C during capillary electrophoresis.

[0106] In some preferred embodiments, the capillary is operated at a temperature of 27-33°C during capillary electrophoresis, preferably 28-32°C, more preferably 29-31°C, for example 29°C, 30°C, 31°C.

[0107] In some embodiments, the sample pan is maintained at a temperature of 10-25°C during capillary electrophoresis, preferably 10-20°C, more preferably 12-18°C, for example 12°C, 15°C, 18°C. Specification 8 / 17 pages 10 CN 121994899 A

[0108] In some embodiments, the capillary may be a chemically inert and hydrophobic capillary.

[0109] In some embodiments, the capillary may be a capillary with a fluorocarbon (FC) polymer coating.

[0110] In some embodiments, the capillary may be commercially available, such as the μSIL-FC capillary from Agilent Technologies. In some exemplary embodiments, the capillary may have an inner diameter of 50 μm, a total length of 50 cm, and an effective length of 40 cm.

[0111] In this invention, there are no particular limitations on the instruments used for the capillary electrophoresis-laser induced fluorescence detection method; for example, commercially available instruments with capillary electrophoresis separation modules and / or LIF detection modules may be used.

[0112] In some exemplary embodiments, the instrument used for the capillary electrophoresis-laser induced fluorescence detection method may be a Sciex 8000 plus analysis system (Sciex) equipped with a solid-state laser induced fluorescence detector (488 nm excitation wavelength and 520 nm emission filter).

[0113] In some exemplary embodiments, the excitation wavelength is set to 488 nm.nm, emission wavelength set to 520 nm.

[0114] In some preferred embodiments, the detection method provided by the present invention adopts the selection of μSIL-FC coated capillary, adjustment of key electrophoresis parameters, and / or combination of fluorescence detection and sample derivatization treatment, which can achieve efficient separation of nine kinds of human milk oligosaccharides in breast milk and infant formula.

[0115] Construction of standard curve

[0116] The establishment of standard curve determines the basis for quantitative analysis comparison, and at the same time, the detection limit and quantitation limit of the detection system or detection method can also be determined.

[0117] The detection method of the present invention also includes the step of constructing standard curve. Specifically, a series of standard substance working solutions of different concentrations are prepared using standard substances of different human milk oligosaccharides. After the above-mentioned sample derivatization steps and the detection method of capillary electrophoresis-laser induced fluorescence, a linear relationship between the calibration peak area and the concentration of standard substances is constructed, and then the content of each human milk oligosaccharide in the sample to be tested is calculated.

[0118] Human milk oligosaccharides

[0119] HMOs are usually composed of 3 to 14 monosaccharides. HMOs are composed of five basic monosaccharide units: glucose, galactose, N-acetylglucosamine, fucose, and N-acetylneuraminic acid. They typically contain a lactose core with a reduced end, which is elongated along with the other three monosaccharide units by the action of several glycosyltransferases. The number of monosaccharide units in their composition is generally 3 to 14.

[0120] Based on whether HMOs are sialylated, they can be divided into neutral HMOs (terminated by L-fucose) and acidic HMOs (terminated by sialic acid).

[0121] In some embodiments, the detection method provided by the present invention can simultaneously detect neutral human milk oligosaccharides and acidic human milk oligosaccharides composed of sialic acid.

[0122] In some embodiments, the detection method provided by the present invention can detect at least one of lactose-N-fucopentose I (LNFP I), lactose-N-tetrasaccharide (LNT), 2'-fucosyllactose (2'-FL), lactose-N-neotetrasaccharide (LNnT), 3,2'-difucosyllactose (DFL), disialyllactose-N-tetrasaccharide (DSLNT), 3-fucosyllactose (3-FL), 3'-sialyllactose (3'-SL), and 6'-sialyllactose (6'-SL).

[0123] In some embodiments, the detection method provided by the present invention can simultaneously detect lactose-N-fucopentose I (LNFP I), lactose-N-tetrasaccharide (LNT), 2'-fucosyllactose (2'-FL), lactose-N-neotetrasaccharide (LNnT), 3,2'-difucosyllactose (DFL), disialyllactose-N-tetrasaccharide (DSLNT), 3-fucosyllactose (3-FL), 3'-sialyllactose (3'-SL), and 6'-sialyllactose (6'-SL).

[0124] Exemplary Embodiments

[0125] In some exemplary embodiments, the present invention provides a method for detecting human milk oligosaccharides based on capillary electrophoresis-laser induced fluorescence detection, page 9 / 17 of the instruction manual, CN 121994899 A, to achieve simultaneous and efficient separation and accurate quantification of nine HMOs in breast milk and infant formula. The specific steps are as follows:

[0126] 1. Preparation of running buffer: The running buffer is an aqueous solution containing 89 mmol / L tris-hydroxymethylaminomethane (Tris-base), 2 mmol / L ethylenediaminetetraacetic acid (EDTA), greater than 2% (m / V) and less than 4% (m / V) polyvinylpyrrolidone (PVP), 4 mol / L urea and greater than 5% (m / V) boric acid.

[0127] 2. Selection and pretreatment of capillary column: Coated capillary column is selected; before use, it is pressure rinsed with hydrochloric acid (HCl) solution; before each injection, it is pressure rinsed with HCl solution, deionized water and running buffer respectively.

[0128] 3. Electrophoresis analysis conditions: (1) Injection method: electric injection; (2) Operating conditions: set separation voltage, capillary temperature, sample tray temperature, and electrophoresis time respectively; (3) Detector: fluorescence detector.

[0129] 4. Sample purification: accurately weigh the breast milk sample or infant formula sample (the infant formula sample needs to be prepared into a premixed solution and mixed with standard), add supercooled ethanol to remove protein impurities. Centrifuge to take the clear liquid, add acetonitrile solution to construct an organic phase dissolution system. Use an amino column to purify the test solution, take an appropriate amount of eluent, blow dry with nitrogen at 50 ℃, and wait for derivatization after rotary drying.

[0130] 5. Sample derivatization labeling: after rotary drying the sample, add the derivatization reagent APTS, add additional acetic acid, and then add the reducing agent sodium cyanoborohydride, open the lid and heat until the liquid evaporates to dryness. After labeling, add deionized water to reconstitute, dilute the breast milk sample and infant formula sample 20 times for injection, and directly inject the mixed standard solution.

[0131] 6. Construction of standard curves: Prepare a mixed standard solution 1 of 9 HMOs, namely 6'-SL, DSLNT, 3'-SL, 3-FL, DFL, LNnT, 2'-FL, LNT, and LNFPⅠ. Dilute the mixed standard stock solution 1 to obtain mixed standard working solutions of 0.1, 0.5, 1, 2, and 5 μg / mL. Purify and derivatize the mixed standard working solutions according to the operations described in steps 4 and 5.

[0132] 7. Quantitative analysis: Separate and detect the derivatized and labeled solutions according to the electrophoretic analysis conditions described in step 3, construct a linear relationship between the calibration peak area and the concentration of the mixed standard working solution in step 5, and calculate the content of each HMO in the breast milk sample or infant formula sample.

[0133] Capillary electrophoresis mainly separates samples based on hydrodynamic volume and charge ratio, and is suitable for most isomers.Excellent resolution is provided. In some preferred embodiments, the present invention proposes a capillary electrophoresis method with laser-induced fluorescence detection and derivatization steps, optimizing detection conditions (injection method, instrument conditions, and buffer concentration) by analyzing a mixed standard of nine selected HMOs standard solutions. The optimal separation of HMOs was finally determined to be achieved by using a background electrolyte (BGE) containing 3% (m / V) polyvinylpyrrolidone (PVP) and 4 M urea as functional additives and 10% (m / V) borate at 30 kV and 30°C, using a 50 μm inner diameter fluorocarbon (FC) capillary with electric injection.

[0134] Examples

[0135] The embodiments of the present invention will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are only for illustrating the present invention and should not be regarded as limiting the scope of the present invention. Unless otherwise specified, the conditions in the examples are performed according to conventional conditions or conditions recommended by the manufacturer. Unless otherwise specified, the reagents or instruments used are conventional products that can be obtained commercially.

[0136] The materials and methods used in subsequent embodiments are as follows.

[0137] 1. Sample Materials

[0138] Urea (item number U5128), sodium cyanoborohydride (item number 296813; 1 mol / L solution), ethylenediaminetetraacetic acid (EDTA, item number E6758), tris-hydroxymethylaminomethane (Tris-base, item number T1503), boric acid (item number B0394), polyvinylpyrrolidone (PVP, item number 437190; Mw1300000), trisodium 8-aminopyrene-1,3,6-trisulfonic acid (APTS, item number 12 CN 121994899 A 09341, page 10 / 17 of the instruction manual), acetic acid (HAc, item number 695092), trifluoroacetic acid (TFA, item number T6508), and ammonia (NH3•H2O, item number 30501) were purchased from Sigma-Aldrich Ltd., USA. Acetonitrile (ACN, catalog number A955-4) and formic acid (FA, catalog number A117) were purchased from Thermo Fisher Scientific, USA. Lactose-N-fucopentose I (LNFP I), lactose-N-tetrasaccharide (LNT), 2'-fucosyllactose (2'-FL), lactose-N-neotetrasaccharide (LNnT), 3,2'-difucosyllactose (DFL), disialyllactose-N-tetrasaccharide (DSLNT), 3-fucosyllactose (3-FL), 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), and lactose were purchased from Wuhan Tangzhi Co., Ltd., China. Deionized water was produced by the Merck Milli-Q water purification system. μSIL- 50 μm inner diameter...FC capillary tubes (catalog number 194-8111) were purchased from Agilent Technologies, Inc., USA. ProElutNH2 amino column (catalog number 63305) was purchased from Dima Technologies, Inc., USA.

[0139] 2. Reagent Preparation

[0140] The running buffer was an aqueous solution containing 89 mmol / L Tris-base, 2 mmol / L EDTA, 3% (m / V) PVP, 4 mol / L urea, and 10% (m / V) boric acid.

[0141] 1% (V / V) trifluoroacetic acid aqueous solution: Pipette 500 μL of trifluoroacetic acid and add water to bring the volume to 50 mL.

[0142] 90% (V / V) acetonitrile aqueous solution: Measure 45 mL of acetonitrile, add 5 mL of water, and mix well.

[0143] 85% (V / V) acetonitrile aqueous solution: Measure 42.5 mL of acetonitrile, add 7.5 mL of water, and mix well.

[0144] 100 mmol / L ammonium formate (pH 4.4): Measure 80 mL of water, add 378 μL of formic acid, adjust the pH to 4.4 with ammonia, and add water to bring the volume to 100 mL.

[0145] 85% acetonitrile aqueous solution containing 15 mmol / L ammonium formate (pH 4.4): Measure 42.5 mL of acetonitrile, add 7.5 mL of 100 mmol / L ammonium formate (pH 4.4), and mix well.

[0146] 3. Sample preparation

[0147] 3.1 Preparation of HMOs standards

[0148] The following 9 HMOs were selected as research objects in the subsequent examples. On the one hand, they are highly abundant in breast milk; on the other hand, according to their structure and chemical properties, they represent the three major categories of HMOs in breast milk: fucose-modified, sialic acid-modified, and unmodified. Weigh 1 mg of 6'-SL, DSLNT, 3'-SL, 3-FL, DFL, LNnT, 2'-FL, LNT, and LNFP I respectively, dissolve them in 1 mL of water, and prepare a 0.1 mg / mL HMOs mixed standard solution 1. Dilute the mixed standard stock solution 1 10 times with acetonitrile to prepare a 10 μg / mL mixed standard stock solution 2. Dilute with 90% (V / V) ACN to obtain mixed standard working solutions of 0.1, 0.5, 1, 2, and 5 μg / mL.

[0149] 3.2 Preparation of breast milk samples

[0150] Weigh 100 mg of breast milk sample into a 1.5 mL centrifuge tube, add 200 μL of supercooled ethanol, and mix well. Centrifuge at 8000 rpm / min for 5 min. Take 210 μL of the supernatant into a 15 mL centrifuge tube, add 1.89 mL of acetonitrile, mix well, collect, and wait for purification.

[0151] 3.3 Preparation of Infant Formula Sample

[0152] Accurately weigh 500 mg of infant formula into a 15 mL centrifuge tube, add 3 mL of 40 ℃ water, vortex to mix,Add water to make up to 5 mL until the infant formula is completely dissolved. Take 1 mL of sample solution and add 2 mL of supercooled ethanol to it, and mix well. Centrifuge at 8000 rpm / min for 5 min. Take 1.2 mL of the clear liquid into a 15 mL centrifuge tube, add 10.8 mL of acetonitrile to it, mix well, and collect for purification.

[0153] 4. Sample purification conditions

[0154] Purification: The amino column was activated with 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution and 3 mL of 85% (V / V) acetonitrile aqueous solution, respectively. Transfer 2 mL of mixed standard (or 2 mL of breast milk sample and 10 mL of infant formula sample) to the column, wash twice with 3 mL of 85% acetonitrile solution containing 15 mM ammonium formate (pH 4.4), and elute with 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution. Collect the elution solution. The volume was adjusted to 3.0 mL with 1% (V / V) trifluoroacetic acid aqueous solution and vortexed. 200 μL of the eluent was taken and dried under nitrogen at 50 °C. The dried sample was left to derivatize. The mixed standard and sample were processed simultaneously.

[0155] 5. Sample Derivatization Conditions

[0156] After the sample was dried, 18 μL of 48 mM APTS (5 mg APTS dissolved in 200 μL of 20% (V / V) acetic acid) was added, along with an additional 5 μL of acetic acid. Then, 2 μL of 1 mol / L sodium cyanoborohydride was added. After vortexing to reconstitute, the sample was heated at 60 °C with the lid off until the liquid evaporated to dryness. After labeling, 100 μL of deionized water was added to reconstitute. Breast milk and infant formula samples were diluted 20 times and injected, while the mixed standard was injected directly.

[0157] 6. Capillary Electrophoresis

[0158] The Sciex 8000 plus analysis system (Sciex) is equipped with a solid-state laser-induced fluorescence detector (488 nm excitation wavelength and 520 nm emission filter) for all capillary electrophoretic separations. The separation buffer is a borate-based buffer (containing PVP and urea) for HMO separation. μSIL-FC capillaries (50 μm inner diameter, 50 cm total length, 40 cm effective length) are run at 30 °C. The sample tray is kept at 15 °C. Separation is performed at a constant normal voltage of 30 kV. The excitation wavelength is set to 488 nm. The emission wavelength is set to 520 nm. New capillaries are rinsed with 0.1 mol / L HCl for 10 minutes before use. The injection procedure is to rinse the capillaries with 0.1 mol / L HCl for 3 minutes, then rinse with water for 2 minutes, and then rinse with running buffer for 5 minutes. The sample is injected at 3 kV for 10 seconds. After injection, a 2-minute voltage ramp is set, increasing the voltage to 30 kV.

[0159] 7. Data Processing

[0160] The content of each HMO in the breast milk sample, X1 (mg / 100g), is calculated according to formula (1); the content of each HMO in the infant formula sample, X2 (mg / 100g), is calculated according to formula (2).

[0161] (1).

[0162] (2).

[0163] Where: X1 and X2 are the contents of each HMO in breast milk and infant formula, respectively, in milligrams per 100 grams (mg / 100g); m1 and m2 are the masses of breast milk and infant formula, respectively, in grams (g); C1 and C2 are the concentrations of each HMO in the breast milk test solution and infant formula test solution obtained from the standard curve, in milligrams per milliliter (μg / mL); n1 and n2 are the dilution factor (30) of the breast milk sample and the dilution factor (60) of the infant formula sample; V is the loading volume of the breast milk and infant formula samples purified by amino column under 90% (V / V) ACN system, in milliliters (mL).

[0164] Example 1: Effect of PVP concentration on the detection of HMOs in dairy products

[0165] The steps are as follows.

[0166] 1. Preparation of running buffer: The running buffer is an aqueous solution containing 89 mmol / L Tris-base, 2 mmol / L EDTA, PVP, 4 mol / L urea and 10% (m / V) boric acid, wherein the amount of PVP added is 2, 3 and 4% (m / V), respectively.

[0167] 2. Selection and pretreatment of capillary column: Use μSIL-FC coated capillary with an inner diameter of 50 μm (total length 50 cm, effective length 40 cm); before first use, rinse the new capillary with 0.1 mol / L HCl at 50 psi pressure for 10 min; before each injection, rinse the capillary with 0.1 mol / L HCl at 50 psi pressure for 3 min, rinse with water at 50 psi pressure for 2 min, and rinse with buffer at 50 psi pressure for 5 min.

[0168] 3. Electrophoresis analysis conditions: A Sciex CESI 8000 plus analysis system equipped with a solid-state laser-induced fluorescence detector was used for detection. The excitation wavelength was set to 488 nm and the emission wavelength was set to 520 nm. Electric injection was used, and the sample was injected at 3 kV for 10 s. A 2-min voltage ramp was set, and the voltage was increased to 30 kV. Separation was carried out at a constant normal voltage of 30 kV for 50 min. The sample plate temperature was 15 ℃ and the capillary temperature was 30 ℃. (Instruction manual, pages 12 / 17, CN 121994899 A)

[0169] 4. Sample purification: 1 mg each of 6'-SL, DSLNT, 3'-SL, 3-FL, DFL, LNnT, 2'-FL, LNT, and LNFP I were weighed and dissolved in 10 mL of water to prepare 0.1...Stock solution 1 of HMOs mixed standard solution (mg / mL). Dilute stock solution 1 10-fold with acetonitrile to prepare a 10 μg / mL mixed standard for purification. Activate the amino column with 3 mL of 1% (v / v) trifluoroacetic acid aqueous solution and 3 mL of 85% (v / v) acetonitrile aqueous solution, respectively. Transfer 2 mL of the mixed standard to the column and wash twice with 3 mL of 85% (v / v) acetonitrile aqueous solution containing 15 mM ammonium formate (pH 4.4). Elute with 3 mL of 1% (v / v) trifluoroacetic acid aqueous solution and collect the eluent. Make up to 3.0 mL with 1% (v / v) trifluoroacetic acid aqueous solution and vortex to mix. Take 200 μL of the eluent, dry under nitrogen at 50 °C, and allow the sample to derivatize after vortexing.

[0170] 5. Sample derivatization and labeling: After vortexing the sample, add 18 μL of 48 mM APTS (5 mg APTS dissolved in 200 μL of 20% (V / V) acetic acid), add an additional 5 μL of acetic acid, then add 2 μL of 1 mol / L sodium cyanoborohydride, vortex to redissolve, and heat at 60 °C with the lid off until the liquid evaporates to dryness. After labeling, add 100 μL of deionized water to redissolve, and inject the mixed standard solution directly.

[0171] 6. Capillary electrophoresis: Separation and detection were performed using a Sciex 8000 plus analysis system (Sciex) equipped with a solid-state laser-induced fluorescence detector according to the electrophoresis conditions in step 3.

[0172] Experimental results: As shown in Figure 1, the PVP concentration does not affect the peak order. The effect of increasing the PVP concentration on different HMOs is different. The separation effect of 3-FL and Lac is better with increasing concentration. At a 2% PVP concentration, the peaks of 3-FL and Lac were not separated from those of 2'-FL and LNnT, while at a 4% PVP concentration, the separation of 3'-SL and 3-FL in the HMOs spectrum was found to be worse. At a 3% PVP concentration, the migration times of the nine HMOs and lactose showed good reproducibility and each sugar could be completely separated, while the detection time was shorter than that at a 4% PVP concentration. At a 3% PVP concentration, acidic oligosaccharides with sialic acid groups (3'-SL, 6'-SL, and DSLNT) achieved good separation in the range of 24 to 33 min.

[0173] Example 2, Effect of boric acid concentration on the detection of HMOs in dairy products

[0174] The steps are as follows: basically the same as the steps in Example 1, except for the following steps.

[0175] 1. Preparation of running buffer: The running buffer is an aqueous solution containing 89 mmol / L Tris-base, 2 mmol / L EDTA, 3% (m / V) PVP, 4 mol / L urea, and boric acid, wherein the amounts of boric acid added are 1%, 5%, and 10% (m / V), respectively.

[0176] Experimental Results: As shown in Figure 2, the concentration of boric acid significantly modulates the peak elution order and separation efficiency of HMOs in capillary electrophoresis. This may be because at low boric acid concentrations, the binding capacity has a greater impact, while at high boric acid concentrations, the stability of the complexes has a greater impact. At a 1% boric acid concentration, the LNFP I and LNT peaks overlap and cannot be effectively separated. At a 5% boric acid concentration, not only is the separation efficiency of LNFP I / LNT not improved, but the electrophoretic peaks of 3-FL / 2'-FL also overlap. However, at a 10% boric acid concentration, all target HMOs exhibit sharp, single, symmetrical peaks without broad peaks or double peaks, indicating a significant improvement in isomer separation efficiency. HMOs, as typical polyhydroxy compounds, have hydroxyl structures in their molecular structure that can reversibly react with borate to form stable anionic complexes. The specificity and stability of this complexation reaction are directly affected by the substituent type, charge distribution, hydroxyl spatial position, and glycosidic bond configuration of the HMO molecule, thereby changing the electrophoretic mobility difference of different HMO molecules in an electric field. The boric acid concentration further amplifies or reduces the above-mentioned mobility difference by regulating the equilibrium state of the complexation reaction (binding ability and complex stability), ultimately achieving selective separation of HMOs with different structures.

[0177] Example 3, Effect of capillary voltage on the detection of HMOs in dairy products

[0178] The steps are as follows: basically the same as the steps in Example 1, except for the following steps.

[0179] 1. Preparation of running buffer: The running buffer is an aqueous solution containing 89 mmol / L Tris-base, 2 mmol / L EDTA, 3% (m / V) PVP, 4 mol / L urea, and 10% (m / V) boric acid.

[0180] 3. Electrophoresis analysis conditions: The Sciex CESI 8000 plus analysis system equipped with a solid-state laser-induced fluorescence detector was used for detection. The excitation wavelength was set to 488 nm and the emission wavelength was set to 520 nm. Electric injection was used, and the sample was injected for 10 s at A kV. A 2-minute voltage ramp was set, and the voltage was increased to 15, 20, and 30 kV respectively. Separation was carried out for 70 min under constant normal voltage. The sample plate temperature was 15 ℃ and the capillary temperature was 30 ℃.

[0181] Experimental results: The instrument voltage directly determines the migration speed of electrophoresis. Too low a voltage will result in too long a migration time, while too high a voltage will accelerate the migration speed and affect the separation effect. As shown in Figure 3, when the voltage is 15 kV, the peak shape of HMOs is relatively wide. Although it can completely separate the 9 HMOs, the migration time is long and the efficiency is too low. Increasing the voltage to 20 kV significantly reduces the migration time of HMOs. At 30 kV, the HMOs exhibit the shortest migration time, fastest separation speed, and best resolution. Meanwhile, at 30 kV...kV is the maximum adjustable voltage of the system. At this time, the current is about -22 μA, the peak shape is the sharpest and the separation is better, which is suitable for high-throughput analysis.

[0182] Example 4, Effect of capillary temperature on the detection of HMOs in dairy products

[0183] The steps are basically the same as those in Example 1, except for the following steps.

[0184] 1. Preparation of running buffer: The running buffer is an aqueous solution containing 89 mmol / L Tris-base, 2 mmol / L EDTA, 3% (m / V) PVP, 4 mol / L urea and 10% (m / V) boric acid.

[0185] 3. Electrophoretic analysis conditions: A Sciex CESI 8000 plus analysis system equipped with a solid-state laser-induced fluorescence detector was used for detection. The excitation wavelength was set to 488 nm and the emission wavelength was set to 520 nm. Electric injection was used, with injection at 3 kV for 10 s. A 2-minute ramp was set, and the voltage was increased to 30 kV. Separation was carried out at a constant normal voltage of 30 kV for 50 min. The sample plate temperature was 15 ℃, and the capillary temperatures were set to 20, 25, 30, and 35 ℃, respectively.

[0186] Experimental results: As shown in Figure 4, under the conditions of 20 ℃ and 25 ℃, the peak migration time of HMOs was too long, resulting in low analysis efficiency. Furthermore, the 3-FL and 3'-SL peaks overlapped, leading to poor separation. Under the condition of 30 ℃, the peak migration time of HMOs was shorter than that at 20 ℃ and 25 ℃, ensuring sufficient time for each HMO to achieve efficient separation while avoiding an excessively long analysis cycle. At 35 ℃, the peak migration time of HMOs is too short, resulting in insufficient peak compression and separation of each HMO (such as poor separation between the LNnT peak and the 2'-FL peak). Therefore, at 30 ℃, the separation of each HMO can be guaranteed, while the analysis time can be shortened and the analysis efficiency improved.

[0187] Application Example 1: Detection of HMOs in breast milk

[0188] The steps are as follows: basically the same as the steps in Example 1, except for the following steps.

[0189] 1. Preparation of running buffer: The running buffer is an aqueous solution containing 89 mmol / L Tris-base, 2 mmol / L EDTA, 3% (m / V) PVP, 4 mol / L urea and 10% (m / V) boric acid.

[0190] 4. Purification of breast milk sample: Accurately weigh 100 mg of breast milk sample into a 1.5 mL centrifuge tube, add 200 μL of supercooled ethanol and mix well. Centrifuge at 8000 rpm / min for 5 min. Take 210 μL of the supernatant into a 15 mL centrifuge tube, add 1.89 mL of acetonitrile, mix well, collect and wait for purification.

[0191] The amino column was purified by 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution and 3 mL of 85% trifluoroacetic acid aqueous solution.Activate with (V / V) acetonitrile aqueous solution, transfer 2 mL of breast milk sample through the column, wash twice with 3 mL of 85% (V / V) acetonitrile aqueous solution containing 15 mM ammonium formate (pH 4.4), elute with 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution, and collect the eluent. Make up to 3.0 mL with 1% (V / V) trifluoroacetic acid aqueous solution and vortex mix. Take 200 μL of eluent, blow dry with nitrogen at 50 °C, and wait for derivatization after vortex drying.

[0192] 5. Derivatization labeling of breast milk sample: After vortex drying, add 18 μL of 48 mM APTS (5 mg APTS dissolved in 200 μL of 20% (V / V) acetic acid), add an additional 5 μL of acetic acid, then add 2 μL of 1 mol / L sodium cyanoborohydride, vortex to reconstitute, and heat at 60 °C with the lid off until the liquid evaporates to dryness. After labeling, add 100 μL of deionized water to reconstitute the sample, and dilute the breast milk sample 20 times before injection.

[0193] 6. Capillary electrophoresis: Separation and detection were performed using a Sciex 8000 plus analysis system (Sciex) equipped with a solid-state laser-induced fluorescence detector, according to the electrophoresis conditions in step 3 (Example 1). Manual 14 / 17 pages 16 CN 121994899 A

[0194] Construction of standard curve: 1 mg of 6'-SL, DSLNT, 3'-SL, 3-FL, DFL, LNnT, 2'-FL, LNT and LNFP I were dissolved in 10 mL of water to prepare a 0.1 mg / mL HMOs mixed standard solution 1. The mixed standard stock solution 1 was diluted 10 times with acetonitrile to prepare a 10 μg / mL mixed standard stock solution 2. Dilute with 90% (V / V) ACN to obtain mixed standard working solutions of 0.1, 0.5, 1, 2, and 5 μg / mL. Take 2 mL of each mixed standard working solution and purify it through an NH2 column. Take 200 μL of the eluent, blow it dry with nitrogen at 50 ℃, label it, add 100 μL of water to redissolve it, and directly inject the mixed standard;

[0195] 7. The content of each HMO in the breast milk sample, X1 (mg / 100g), is calculated according to the formula: .

[0196] Wherein: X1—content of each HMO in breast milk, in milligrams per 100 grams (mg / 100 g); m1—mass of breast milk, in grams (g); C1—concentration of each HMO in the breast milk sample obtained from the standard curve, in micrograms per milliliter (μg / mL); n1—dilution factor of the breast milk sample (30); V1—sample loading volume of breast milk sample purified using an amino column in a 90% (V / V) ACN system, in milliliters (mL).

[0197] Experimental results: The detection method adopted in this invention can separate HMOs within the range of 20-40 min, andIt can be applied to breast milk matrix. This invention reduces protein, lactose, salt and other possible interferences through pretreatment methods such as alcohol precipitation to remove proteins and amino column purification. The electrophoretic spectra of the nine HMOs and lactose standards are shown in Figure 5. The calibration curve was constructed by the relationship between the peak area and the corresponding concentration of the HMO mixed standard, and the results are shown in Table 1. The calibration curve has a good linear relationship in the range of 0.1 ~ 5 μg / mL, the correlation coefficient R2 is greater than 0.995, and the average relative residual standard deviation error is less than 5%.

[0198] The electrophoretic spectra of the breast milk sample are shown in Figure 6. When evaluating the accuracy and repeatability of the breast milk matrix detection method, the breast milk sample containing a certain concentration of HMOs was tested 10 times to obtain the accurate HMOs content. Three concentrations of HMOs standard samples with low, medium and high concentrations within the linear range were added to this sample, and 10 repeated tests were performed for each spiked concentration. The results are shown in Table 2. The results showed that the recoveries of all HMOs components were between 93.3% and 100.8%; the RSD of the 10-time repeatability precision at all three levels was less than 4.6%, meeting the relevant requirements in GB 5009.295-2023. The overall recovery rate and precision met the quantitative requirements for the use of this method in breast milk.

[0199] When evaluating the sensitivity of the breast milk matrix detection method, ultrafiltration (molecular weight cutoff of 10 kDa) was used to remove substances below 10 kDa (including HMOs) from the matrix as a sample matrix blank. By adding a known concentration of HMOs solution to the blank sample solution, the minimum HMOs concentration that the instrument could recognize was repeatedly tried to obtain. This concentration value was measured 10 times and this concentration value was used as the limit of detection (LODHMOS) for HMOs. 3.3 times the LODHMOS was used as the limit of quantitation (LOQHMOS). The results are shown in Table 2. The detection limit and quantitation limit of the method of the present invention are at extremely low concentration levels, which can cover the trace to conventional concentration range of HMOs in actual samples, meet the requirements of accuracy, sensitivity and stability of separation and detection, and can be used for high-throughput analysis of actual samples.

[0200] Table 1. Linear range of the method for detecting HMOs Instruction manual 15 / 17 pages 17 CN 121994899 A

[0201]

[0202] Table 2 Validation of the method for detecting HMOs in breast milk (n=10)

[0203]

[0204] Application example 2, detection of HMOs in infant formula

[0205] The steps are as follows: The steps are basically the same as those in application example 1, except for the following steps.

[0206] 4. Purification treatment of infant formula sample: Accurately weigh 500 mg of infant formula into a 15 mL centrifuge tube, add 3 mL of 40 ℃ water, vortex and mix until the infant formula is completely dissolved, and add water to make up to 5 mL. Take 1 mL of sample solution and add 2 mL of supercooled ethanol, then mix thoroughly. 8000Centrifuge at rpm / min for 5 min. Take 1.2 mL of the supernatant into a 15 mL centrifuge tube, add 10.8 mL of acetonitrile, mix well, and collect for purification.

[0207] The amino column was activated with 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution and 3 mL of 85% (V / V) acetonitrile aqueous solution, respectively. Transfer 10 mL of infant formula sample through the column, wash twice with 3 mL of 85% (V / V) acetonitrile aqueous solution containing 15 mM ammonium formate (pH 4.4), and elute with 3 mL of 1% (V / V) trifluoroacetic acid aqueous solution. Collect the eluent. Make up to 3.0 mL with 1% (V / V) trifluoroacetic acid aqueous solution and vortex to mix. Take 200 μL of the eluent, blow dry with nitrogen at 50 °C, and wait for derivatization of the sample after vortex drying.

[0208] 7. The content of each HMO in the infant formula sample, X2 (mg / 100g), is calculated according to the formula: . Instructions 16 / 17 pages 18 CN 121994899 A

[0209] Where: X2——content of each HMO in the infant formula, in milligrams per 100 grams (mg / 100g); m2——mass of the infant formula, in grams (g); C2——concentration of each HMO in the infant formula test solution obtained from the standard curve, in micrograms per milliliter (μg / mL); n2——dilution factor of the infant formula sample (60); V2——sample loading volume of the infant formula sample in the 90% (V / V) ACN system purified by an amino column, in milliliters (mL).

[0210] Experimental results: The detection method adopted in this invention can be applied to the infant formula matrix to separate HMOs in the range of 20-40 min. The electrophoretic spectrum of the infant formula sample is shown in Figure 7. The accuracy, repeatability and sensitivity of the detection method applied to the infant formula matrix were evaluated, and the results are shown in Table 3. The recoveries of all HMOs components were between 90.7% and 101.2%; the RSD of the 10-time repeatability precision at the three levels was less than 4.5%, which meets the relevant requirements in GB 5009.295-2023. The method of the present invention can realize the quality control and label compliance verification of infant formula by comparing the content of HMOs in the detection of infant formula with the fortified content claimed by the product.

[0211] Table 3 Validation of the method for detecting HMOs in infant formula (n=10)

[0212]

[0213] It should be noted that although the technical solution of the present invention has been introduced with specific examples, those skilled in the art can understand that the present invention should not be limited thereto.

[0214] Various embodiments of the present invention have been described above. The above description is exemplary and not exhaustive, and is not limited to the disclosed embodiments. Without departing from the scope and spirit of the described embodiments, the present invention can be applied to other related technologies.Many modifications and changes will be obvious to those skilled in the art. The terminology used herein is chosen to best explain the principles of the embodiments, their practical application, or improvements to the technology in the market, or to enable others skilled in the art to understand the embodiments disclosed herein. Instruction manual, page 17 / 17, 19 CN 121994899 A, Figure 1; Instruction manual, Figure 1 / 7, page 20 CN 121994899 A, Figure 2; Instruction manual, Figure 2 / 7, page 21 CN 121994899 A, Figure 3; Instruction manual, Figure 3 / 7, page 22 CN 121994899 A, Figure 4; Instruction manual, Figure 4 / 7, page 23 CN 121994899 A, Figure 5; Instruction manual, Figure 5 / 7, page 24 CN 121994899 A, Figure 6; Instruction manual, Figure 6 / 7, page 25 CN 121994899 A, Figure 7; Instruction manual, Figure 7 / 7, page 26 CN 121994899 A, Abstract: The present invention discloses a detection method of breast milk oligosaccharide. The present invention provides a detection method of breast milk oligosaccharide, which comprises the step of detecting a sample to be detected by using a detection method based on capillary electrophoresis-laser induced... fluorescence,wherein, an operation buffer solution used in the detection method based on capillary electrophoresis-laser induced fluorescence comprises Tris-base, EDTA and urea, and PVP greater than 2% (m / V) and less than 4% (m / V) and boric acid greater than 5% (m / V) and less than 15%(m / V). The detection method provided by the present invention can be applied to separation and detection of acidic and neutral HMOs isomers in samples to be detected (such as breast milk and infant formula milk powder samples).